 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: LEMTRADA (Campath, alemtuzumab) |
|
***************************************************** |
|
#Post#: 3247-------------------------------------------------- |
|
Impact of previous DMT on effectiveness, safety outcomes in PwMS |
|
treated w/Lemtrada |
|
By: agate Date: April 5, 2021, 7:17 pm |
|
--------------------------------------------------------- |
|
From the Journal of Neurology, Neurosurgery and Psychiatry |
|
(April 5, 2021), "Impact of previous disease-modifying |
|
treatment on effectiveness and safety outcomes, among patients |
|
with multiple sclerosis treated with alemtuzumab": |
|
https://jnnp.bmj.com/content/early/2021/03/11/jnnp-2020-325304.long |
|
A summary of the findings is in Multiple Sclerosis News Today |
|
(April 5)--"Moving from Gilenya to Lemtrada May Not Be Optimal |
|
Choice, Study Says": |
|
https://multiplesclerosisnewstoday.com/news-posts/2021/03/17/impact-of-previous… |
|
***************************************************** |
